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Objective: The data on England and Wales voluntarily supplied
by Coroners to the National Programme on Substance Abuse
Deaths for the August 1996-December 2002 time frame were
analyzed.Methods: All cases inwhich at least one analgesic- and
cough suppressant-opioid other than heroin/morphine, metha-
done or buprenorphine was identified were extracted from the
database. We hypothesized that: a) populations of addicts and
non-addicts presented differences in patterns of drugs involved;
and b) within the population of addicts and non-addicts, inten-
tional and non-intentional deaths presented different patterns of
substance consumption. Results: A total of 2024 deaths related
to selected opioids, either alone or in combination, were in-
cluded in the analysis. Typically, non-addicts were older than
45 and died as a result of intentional poisoning whilst majority of
addicts were young, males and victims of accidental deaths. In
about 93% of cases the selected opioids were reported in combi-
nation with another substance. Most frequently identified nar-
cotics were propoxyphene, codeine and dihydrocodeine. Co-
proxamol, Co-codamol and Co-dydramol were typically pre-
scribed for non-addicts, whilst dihydrocodeine was mostly given
to addicts. In non-addicts, alcohol was mostly represented in
accidental deaths and antidepressants were typically repre-
sented in intentional deaths. Conversely, illicit drugs and hypno-
tics/sedatives were typically reported in addicts’ accidental
deaths. Conclusions: The present report constitutes the largest
available collection of analgesic- and cough suppressant-opioid
mortality data in the UK. Users should be educated about risks
associated with polydrug misuse.
Introduction
The opioid preparation group is huge [15] and includes illicitly-
used compounds (e.g. heroin) as well. Methadone and buprenor-
phine are widely used for the treatment of opioid dependence,
while most of the remaining compounds, including dextropro-
poxyphene, dextromoramide, dihydrocodeine, dipipanone, fen-
tanyl, meptazinol, tramadol, and oxycodone are usually
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prescribed as narcotic analgesics. A few of them, e.g. codeine
phosphate, may be acquired as over-the-counter analgesic med-
ications, whilst others (e.g. dextromethorphan, pholcodine) are
administered as cough-suppressants. Dextropropoxyphene, co-
deine and dihydrocodeine are available in the UK market in
combination with paracetamol with the propriety names, Co-
proxamol, Co-codamol and Co-dydramol, respectively. Opioid
abuse potential may be considerable; tolerance and dependence
may develop quickly and cross-tolerance exists between vir-
tually all the compounds of this class [15].
At present, there is only one special mortality register in the UK
that publishes information on drug related deaths, the National
Programme on Substance Abuse Deaths (np-SAD) at St George’s,
University of London. The np-SAD database was started in July
1997; information from this database is published in both
6–monthly and annual reports on cases notified voluntarily by
Coroners in England and Wales. Coroners in Northern Ireland,
the Isle of Man and the Channel Islands, as well as some
Procurators Fiscal in Scotland, have recently started submitting
information to the Programme [14].
Although the overdose effects of the compounds which are
traditionally linked to the drug addiction scene, e.g. heroin [20]
and methadone [6], have already been commented on, there is
still a lack of information regarding the analgesic- and cough
suppressant-opioids’ mortality data. Furthermore, the role of
intentionality in fatalities involving the prescription of opioid
analgesics is a cause of concern. Schifano et al. [28] recently
reported that buprenorphine, mostly prescribed as analgesic,
was implicated in forty-three fatalities in the UK during the
period 1980–2002. Twenty-eight percent of cases were suicides;
most of them were over 45 and none was known as drug addict.
The aim of this research was to achieve a better understanding of
the issue of deaths related to analgesic- and cough suppressant-
opioids. We aimed at focussing on England and Wales np-SAD
figures for the August 1996–December 2002 time frame. We
hypothesized that: a) populations of addicts and non-addicts
presented differences in patterns of drugs involved; and b) with-
in the population of addicts and non-addicts, intentional and
non-intentional deaths presented different patterns of substance
consumption.
Methods
Deaths were included on the np-SAD database if, according to the
formal Coroner’s verdict, one or more psychoactive substances
were directly implicated in death, if the patient had a history of
dependence on or misuse of psychoactive drugs, or if controlled
drugs were found during necropsy. Alcohol was included only
when implicated in combination with other qualifying drugs.
When Coroners’ inquests were complete, cases were reported by
demographic characteristics, time and place of death, whether
they were prescribed medication(s), history of drug addiction,
psychoactive substances found at post-mortem (including alco-
hol), causes of death and any other information that Coroners
considered to be relevant. By December 31, 2003, the np-SAD
database included a total of 8,209 drug-related deaths occurring
in England and Wales in the time frame August 1996–December
2002. We extracted all cases in which at least one analgesic- and
cough suppressant-opioid was identified by Coroners. Cases in
which heroin/morphine, methadone or buprenorphine were
identified were included only if these molecules were in associa-
tion with a qualifying analgesic- and cough suppressant-opioid.
There are difficulties in distinguishing heroin- from morphine-
intoxication cases at post mortem [13]. For the purpose of this
study, those victims in which either heroin, or morphine, or both
were identified, were assembled together in the heroin/mor-
phine category.
For further analysis, the cases involving analgesic- and cough
suppressant-opioids were divided into two subgroups: addicts
and non-addicts. A drug abuser/addict case was identified when
one or more of the following criteria were met: a) reported as a
known illicit drug user by the Coroner, based on evidence
obtained at inquest; b) prescribed substitutemedication for drug
dependence; c) presence of an illicit drug at post mortem, where
not prescribed, or d) presence of any additional information on
the Coroner’s report suggestive of a history of drug abuse and
where such a history fulfilled ICD-10 [32] criteria.
Deaths were also classified as either intentional (e.g. suicide) or
accidental in line with the Coroner’s verdict. To test for possible
differences between subgroups of intentional and accidental
deaths, cases of fatalities where the cause of death was unascer-
tained were excluded from the analysis.
Statistical Analysis
Analyses were performed using the Statistical Package for the
Social Sciences, version 10 for Windows. Demographic details,
risk factors and categorical data were expressed as percentages
within groups, and compared with the Pearson chi-squared test
(two-tailed) or Fischer’s exact test if appropriate. The results for
statistical tests were regarded as significant at or below the 5%
probability level.
Results
A total of 2024 deaths (24. 7% of all fatalities) related to analge-
sic- and cough suppressant-opioids, either alone or in combina-
tion, were included in the analysis. Selected opioids were
mentioned either in the toxicological post-mortem analysis
(574, 28.4 %) or in the Coroner’s verdict (415, 20.5 %) or in both
(1035, 51.2 %). Number of deaths related to analgesic- and cough
suppressant-opioids showed a peak in 2001, with 441 related
fatalities recorded. Most of non-addicts were older than 45 and
died as a result of an intentional poisoning whilst majority of
addicts were young, males and victims of accidental deaths
(Table 1 ).
In about 93% of cases the analgesic- and cough suppressant-
opioids were reported in combination with another substance
(either psychoactive or not), with polydrug ingestion being sig-
nificantlymore represented in addicts (Table 2 ). Most frequently
identified narcotic analgesic was dextropropoxyphene/propoxy-
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phene, which was mostly identified in non-addicts. Conversely,
codeine and dihydrocodeine were equally identified in both
addicts and in non-addicts. Most frequent associated psychoac-
tive substance in both groups was alcohol, identified in about
36% of cases. Antidepressants were mostly identified in non-
addicts; less frequently reported narcotics (including dextromor-
amide and the cough-suppressants pholcodine, noscapine and
dextromethorphan) were mostly identified in addicts, together
with heroin/morphine; methadone; hypnotics/sedatives; stimu-
lants and cannabis. In addicts, heroin/morphine was associated
with codeine in 405 cases (93.0 % of codeine-related deaths in
addicts).
Analgesic- and cough suppressant-opioids were prescribed in
772 cases (38.1% of the total sample), with a prescription being
given more frequently to non-addicts than to addicts (Table 3 ).
Table 1 Deaths related to analgesic- cough suppressant-opioids, England and Wales, 1996–2002. Gender, age and cause of death;
comparisons between non addict and addict subgroups
Total Sample (N = 2024) Non-addicts (N = 1114) Addicts (N = 910) p Values
Gender
Male 1345 (66.5%) 601 (53.9%) 744 (81.8%) w2 = 173.740, df = 1, p < .001
Female 679 (33.5%) 513 (46.1%) 166 (18.2%)
Age group
< 24 264 (13%) 103 (9.2%) 161 (17.7%) w2 = 357.081, df = 5, p < .001
25–34 577 (28.5%) 199 (17.9%) 378 (41.5%)
35–44 482 (23.8%) 244 (21.9%) 238 (26.2%)
45–54 299 (14.8%) 205 (18.4%) 94 (10.3%)
55–64 165 (8.2%) 140 (12.6%) 25 (2.7%)
> 65 237 (11.7%) 223 (20.0%) 14 (1.5%)
Cause of death
accidental 1242 (61.4%) 486 (43.6%) 756 (83.1%) w2 = 333.168, df = 2, p < .001
suicide 633 (31.3%) 516 (46.3%) 117 (12.9%)
unascertained 149 (7.4%) 112 (10.1%) 37 (4.1%)
w2 = Pearson’s chi square value; p = significance.
Table 2 Deaths related to analgesic- cough suppressant-opioids, England and Wales, 1996–2002. Selected opioids and psychoactive
substances identified; comparisons between non addicts and addicts (please note that totals do not equal number of cases due to
multiple drugs implicated in most cases)
Total sample
(N = 2024): number of
deaths in which the
index opioid was
identified
Non-addicts subgroup
(N = 1114): number of
deaths in which the
index opioid was
identified
Addicts subgroup
(N = 910): number of
deaths in which the
index opioid was
identified
p values (df = 1)
Index analgesic- and cough suppressant-opioid
in combination with another opioid and/or with
another substance
1878 (92.8%) 988 (88.7%) 890 (97.8%) w2 = 62.143, p < .001
Analgesic- and cough suppressant-opioid alone 146 (7.2%) 126 (11.3%) 20 (2.2%)
Index analgesic- and cough suppressant-opioids
Dextro-propoxyphene containing compounds 891 (44.0%) 726 (65.2%) 165 (18.1%) w2 = 449.718, p < .001
Codeine containing compounds 563 (27.8%) 126 (11.3%) 437 (48.0%) w2 = 336.186, p < .001
Dihydrocodeine containing compounds 556 (27.5%) 246 (22.1%) 310 (34.1%) w2 = 36.099, p < .001
Tramadol 75 (3.7%) 47 (4.2%) 28 (3.1%) w2 = 1.831, p = .176
Others (each represented in less than 2% of
total number of cases): dipipanone; pethidine;
dextromoramide; meptazinol; pholcodine;
noscapine; dextromethorphan; fentanyl;
pentazocine; alfentanil; oxycodone
90 (4.4%) 39 (3.5%) 51 (5.6%) w2 = 5.22, p = .0224
Psychoactive substances associated
Alcohol 721 (35.6%) 394 (35.4%) 327 (35.9%) w2 = .070, p = .791
Hypnotics/sedatives 598 (29.6%) 198 (17.8%) 400 (44.0%) w2 = 164.942, p < .001
Opiates (i.e.: morphine and/or heroin/morphine
and/or methadone)
722 (35.7%) 47 (4.2%) 675 (74.2%) w2 = 1068.190, p < .001
Antidepressants 325 (16.1%) 203 (18 .2%) 122 (13.4%) w2 = 8.619, p = .003
Antipsychotics 42 (2.1%) 23 (2.1%) 19 (2.1%) w2 = .001, p = .971
Psychostimulants (i.e. ecstasy, cocaine,
amphetamine)
163 (17.9%) 0 163 (17.9%) w2 = 217.018, p < .001
Cannabis 92 (4.5%) 0 92 (10.1%) w2 = .117.987, p < .001
w2 = Pearson’s chi square value; p = significance.
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For the whole sample, the most frequently identified prescribed
compound was Co-proxamol, followed by dihydrocodeine. Co-
proxamol, Co-codamol and Co-dydramol were mostly prescribed
for non-addicts, whilst dihydrocodeine was mostly prescribed
for addicts.
Polydrug ingestion was mostly observed in accidental deaths, in
both addicts and non-addicts (Table 4 ). In non-addicts, alcohol
was mostly represented in accidental deaths and antidepres-
sants were typically represented in intentional deaths. Dextro-
propoxyphene-containing compounds were mostly represented
in intentional deaths in both groups. Conversely, codeine-con-
taining compounds; illicit drugs and hypnotics/sedatives were
typically reported in addicts’ accidental deaths.
Discussion
To the best of our knowledge, the present report constitutes the
largest available collection of analgesic- and cough suppressant-
opioid mortality data in the UK. Index opioids were identified,
either alone or in combination, in well about 25% of total cases
flagged in the 1996–2002 np-SAD data base. Consistent with our
hypotheses, it was found here that populations of addicts and
non-addicts presented differences in patterns of drugs involved.
Furthermore, within the population of addicts and non addicts,
intentional and non intentional deaths presented with different
patterns of substance intake.
Data from the 2002 US Drug Abuse Warning Network (DAWN)
report on drug abuse-related Medical Examiner cases [25] seem
to be consistent with high rates of identification of analgesic-
and cough suppressant-opioids given here. In fact, a narcotic
analgesic ranked in the top 3 most frequently DAWN reported
drugs in most important US cities, including New York, New
Orleans, Atlanta, Buffalo and San Francisco.
Similarly to previous literature [7], most (83%) addicts died here
as a result of accidental deaths. Conversely, and in parallel with
previous UK observations of deaths related to narcotic analgesics
Table 3 Deaths related to analgesic- cough suppressant-opioids, England and Wales, 1996-2002. Prescribed opioids identified and
comparisons between non addicts and addicts (please note that the totals do not equal number of cases due to multiple drugs
implicated in most cases)
Total sample (N = 2024):
number of deaths in which
the identified opioid
resulted to be prescribed
Non-addicts subgroup
(N = 1114) number of
deaths in which the
identified opioid resulted
to be prescribed
Addicts subgroup (N = 910)
number of deaths in which
the identified opioid
resulted to be prescribed
p values (df = 1)
Prescribed analgesic- and cough
suppressant-opioids
772 (38.1%) 542 (48.6%) 230 (25.3%) w2 = 119.675, p < .001
Co-proxamol 376 (50.9%) 322 (28.9%) 54 (5.9%) w2 = 174.720, p < .001
Co-codamol 52 (18.6%) 38 (3.4%) 14 (1.5%) w2 = 7.025, p = .03
Co-dydramol 19 (0.9%) 16 (1.4%) 3 (0.3%) w2 = 6.595, p < .01
Dihydrocodeine 238 (11.8%) 114 (10.2%) 124 (13.6%) w2 = 5.557, p = .018
w2 = Pearson’s chi square value; p = significance.
Table 4 Deaths related to analgesic- cough suppressant-opioids, England and Wales, 1996-2002. Comparisons between accidental and
intentional deaths in both non addicts and addicts in terms of psychoactive substances identified. (Please note that only
statistically significant results are here provided)
Non-addicts Addicts
Non-addicts
accidental deaths
(N = 486)
Non-addicts
intentional
deaths
(N = 516)
p values (df = 1) Addicts
accidental
deaths (N = 756)
Addicts
intentional
deaths (N = 117)
p values (df = 1)
Selected analgesic- and cough
suppressant-opioid in
combination with another opioid
and/or with another substance
307 (63.2%) 281 (54.5%) w2 = 7.833, p = .005 722 (95.5%) 99 (84.6%) w2 = 21.439, p < .001
Dextro-propoxyphene-containing
compounds
304 (62.6%) 335 (68.8%) w2 = 4.338, p = .037 111 (14.7%) 42 (35.9%) w2 = 31.549, p < .001
Alcohol 195 (40.1%) 154 (29.8%) w2 = 11.649, p = .001
Antidepressants 80 (16.5%) 111 (21.5%) w2 = 4.138, p = .042
Codeine-containing compounds 390 (51.6%) 35 (29.9%) w2 = 19.050, p < .001
Illicit drugs (i.e.: heroin/morphine;
psycho-stimulants; cannabis)
605 (80%) 49 (41.9%) w2 = 78.451, p < .001
Hypnotics/sedatives 348 (46%) 38 (32.5%) w2 = 7.545, p = .006
w2 = Pearson’s chi square value; p = significance.
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(e.g. buprenorphine; [28]), the number of intentional poisoning
cases was considerably high (46%) in non-addicts. Most fre-
quently identified compounds were those containing dextropro-
poxyphene, which were reported in 44% of cases examined.
Codeine and dihydrocodeinewere reported in about 28% of cases
each and a smaller number of deaths were related to other
narcotic analgesics, e.g. tramadol.
Co-proxamol clearly accounted here for most prescriptions. Re-
ports of poisoning with compounds containing dextropropoxy-
phene have been frequently reported in the literature [17],
probably due to their predominance in the market [22]. Anti-
depressants and dextropropoxyphene-containing compounds
were heremostly represented in non-addicts’ intentional deaths.
Dextropropoxyphene was arguably prescribed for pain control
and one might hypothesize a possible association between
chronic pain and depression [2], which may in turn have led to
suicide. It has been suggested that restriction of Co-proxamol
availability could have an important role in suicide prevention
[31]; the compound is being gradually withdrawn from the UK
market [23].
Cases with a history of drug addiction accounted for 45% of cases
studied. Dihydrocodeine was typically given to addicts and one
could wonder if prescription occurred for the treatment of drug
addiction itself. Although in contrast with indications issued in
the Department of Health guidelines [9], dihydrocodeine is fre-
quently prescribed by individual physicians for harm reduction
purposes [27]. In combination with a general acceptance for this
drug as a substitute for methadone amongst Scottish general
practitioners, in the Strathclyde region an increase in the number
of drug related deaths over a five-year period has been reported
[30].
Although codeine-containing compounds were here mostly pre-
scribed to non-addicts, codeinewas typically identified in addicts.
Polydrug users may report a preference for codeine [11], but one
should take also into account that the toxicological analysis of a
‘heroin’ dose can present an association of heroin, morphine and
codeine [13]. Consistently with this, heroin/morphine was here
associated with 93% of codeine related-deaths in addicts.
In about 93% of cases, analgesic- and cough suppressant-opioids
were reported in combination with another substance, with
polydrug ingestion being significantly more represented in ad-
dicts. Almost exclusively, deaths associated with opiates/opioids
also involve a cocktail of drugs, such as alcohol and benzodiaze-
pines [15,18]. In confirming this, alcohol and hypnotics/sedatives
were here respectively identified in about 36% and 30% of the
whole sample of described fatalities. Sedatives may enhance the
respiratory depressive effects of opioids and together form a fatal
combination [6]. Conversely, antidepressants were mostly iden-
tified in association with opioids in non-addicts. The phenylpi-
peridine series of opioids, including pethidine, tramadol,
dextromethorphan and propoxyphene, appear to be weak sero-
tonin re-uptake inhibitors and may be involved in serotonin
toxicity reactions, including some fatalities, in association with
serotonergic antidepressants [16].
One could wonder about the reasons behind high rates of
identification of opioids in combination with other drugs found
here. Whilst in opiate addicts high rates of drug combination
patterns may be explained by their medication-seeking beha-
viour, the 89% drug combination rate found in non-addicts is an
intriguing issue. Furthermore, themedical reasons behind opioid
prescription itself to non-addict victims were unclear here.
Opioid analgesics might be appropriately prescribed in cancer-
related painful conditions only; in fact, available evidence in-
dicates that oral opioids generally achieve only modest reduc-
tions in pain levels in patients with chronic non-cancer pain [24].
Although we did not aim here at identifying cancer prevalence
figures in victims prescribed with opioid analgesics, occurrence
of meaningful rates of neoplasms in the present sample should
be considered very unlikely. In fact, in the ‘cause of death’ section
of Coroners’ reports, rates of cancer recording as a contributory
factor were negligible indeed. On the other hand, present data
are consistent with observation of rising prescription rates of
opioids in non-malignant conditions in other countries, includ-
ing the US [3, 4], and Sweden [19], and especially so in older
adults. One out of 2 of non-addict victims were here older than
45. Apart from cancer, frequently observed painful conditions in
this age range include facet joint arthritis (causing low back
pain), polymyalgia rheumatica, neuropathies, peripheral vascu-
lar disease and coronary disease [8]. On the other hand, uncri-
tical prescription of narcotic analgesics may be the reason of
serious concern. Though the use of opioid analgesics for the
treatment of acute pain appears to be generally benign, long-
term administration of opioids has been associated with clini-
cally meaningful rates of abuse or addiction [4]. Furthermore, it
has been suggested that pain intensity is not consistent with
opioid prescription; age, depression, personality disorder, and
history of substance abuse was closely linked to the use of
opioids for the treatment of back pain in preference to nonster-
oidal anti-inflammatory drugs alone [1]. Opioid choices necessi-
tate an understanding of pharmacology to ensure safe
administration and avoidance of drug interactions. Possible
multifaceted solutions exist to improve physicians’ ability to
treat patients appropriately. Examples include comprehensive,
practical multidimensional guidelines on the evaluation and
treatment of chronic non-malignant pain; enhanced continuing
medical education and pregraduate training; and multispecialty
coordinated care of patients [26].
A possible limitation of the present study is given by our defini-
tion of deaths related to analgesic- and cough suppressant-
opioids, which was as comprehensive as possible. On a number
of cases here presented, in fact, index opioids were mentioned in
the coronial documents even if their role in the final cause of
death was unclear. It has been suggested that in cases of multiple
drug fatalities cause of death should not be attributed to any
single drug. Rather, the unique combination of drugs, the pattern
of drug use/abuse, and individual factors, such as tolerance to the
respiratory depressant effects of opioids, must be taken into
account in the formulation of a valid cause of death statement
[5]. This possibly ‘overinclusive’ methodological approach [14]
has been chosen to add as much information as possible to the
very limited knowledge available on opioid administration
safety issues in the UK. Although we feel confident that all
opioid-related deaths that have been so diagnosed and appro-
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priately reported by Coroners have been identified with the
chosen data collection methods, changes in reporting over time
should be taken into account here to interpret these findings. In
fact, although in the last few years the response rate from
Coroners in England and Wales has been estimated to have been
as high as about 95% [14,15], in 1996–1998 the np-SAD Cor-
oners’ response rate was of only about 50%. One can think that
Coroners’ determinations may have been subject to biases. In
fact some Coroners, in deciding whether a person was an addict
or not, and whether a death was intentional or not, may con-
sciously or unconsciously have used information on the nature
and dose of drugs ingested. Furthermore, some Coroners may
have preferred, where possible, to spare families the added
anguish of a verdict of suicide. As a consequence, the frequency
of intention may have been underestimated here. Another po-
tential limitation of the present study is given by the lack of
presentation of comprehensive toxicology data. On the other
hand, post mortem toxicology examination is not routinely
carried out in all cases in the UK [28, 29]. Positivity of opioids
in the toxicology results was not the only criterion used here to
define an opioid-related death, since Coroners may have had
access to other information, including evidence from the scene,
witnesses’ statements and list of prescribed medications, to
make their own final and formal judgement. Finally, a number
of medications here commented (i.e. Co-proxamol, Co-codamol
etc), are typically available in the UK but not necessarily in other
countries and this may limit the generalisation of present data.
Although there are numerous deaths associated with opioids
each year, many of them are preventable. It may be concluded
from here that much still needs to be done in educating the users
about the risks associated with polydrug use, especially of mix-
ing opioids, alcohol, benzodiazepines and antidepressants
[16,18]. Index opioids implicated in deaths were here prescribed
in only about half of non-addicts and in about one fourth of
addicts. Although low prescription rates shown here may be
accounted by possible inconsistencies in information written in
Coroners’ reports, one could wonder how most victims accessed
their opioids. The opioid source may be a family member or
partner [18], but over the counter (OTC) availability of some of
the opioids here commented may be a cause of concern. In the
UK, pharmacists perceive abuse and misuse of OTC products to
be occurring in practice [21] and current methods employed for
dealing with it are felt to be inadequate [12].
Improvements in the monitoring of opioid prescribing and dis-
pensing, especially while treating chronic pain patients [10],
should help to reduce in the UK the number of deaths involving
these compounds. Analgesic- and cough suppressant-opioids,
like any other compound, may be toxic if not taken appropriately.
They have to be administered in the right amount, to the right
individuals and for the correct indication.
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